Compare Stocks

→ Biden Nomination CANCELED? (From The Freeport Society) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$1.70 -5.0%	$1.78	$0.77 ▼ $14.00	$6.89M	1.41	7.92 million shs	107,846 shs
CVKD Cadrenal Therapeutics	$0.49 +6.5%	$0.55	$0.36 ▼ $3.14	$7.85M	1.64	502,401 shs	439,573 shs
PTIX Protagenic Therapeutics	$1.28 -6.6%	$1.37	$0.68 ▼ $2.32	$5.68M	0.44	9,502 shs	1,837 shs
YMTX Yumanity Therapeutics	$0.59 +5.4%	$0.73	$0.95 ▼ $13.23	$6.40M	0.32	473,083 shs	67,152 shs

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	0.00%	+5.59%	+39.34%	+51.79%	-77.50%
CVKD Cadrenal Therapeutics	0.00%	+13.94%	-19.34%	-63.67%	-59.80%
PTIX Protagenic Therapeutics	0.00%	-7.58%	-22.42%	+31.96%	-31.18%
YMTX Yumanity Therapeutics	0.00%	-3.30%	+5.81%	-77.22%	-85.65%

Gold Mania (Ad)

Former Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).

See his free reveal right here.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	2.1989 of 5 stars	3.5	3.0	0.0	0.0	0.6	1.7	1.3
PTIX Protagenic Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
YMTX Yumanity Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	3.00	Buy	$3.50	613.56% Upside
PTIX Protagenic Therapeutics	N/A	N/A	N/A	N/A
YMTX Yumanity Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest ADIL, YMTX, CVKD, and PTIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/14/2024	CVKD Cadrenal Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00

(Data available from 5/5/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$2.46 per share	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	$0.59 per share	N/A
PTIX Protagenic Therapeutics	N/A	N/A	N/A	N/A	$0.83 per share	N/A
YMTX Yumanity Therapeutics	$4.84M	1.32	N/A	N/A	$2.28 per share	0.26

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$5.12M	-$5.72	N/A	N/A	N/A	N/A	-250.52%	-183.24%	5/10/2024 (Estimated)
CVKD Cadrenal Therapeutics	-$8.36M	-$0.69	N/A	N/A	N/A	N/A	-128.67%	-117.76%	5/8/2024 (Estimated)
PTIX Protagenic Therapeutics	-$5M	-$1.15	N/A	∞	N/A	N/A	-101.81%	-82.18%	5/20/2024 (Estimated)
YMTX Yumanity Therapeutics	-$39.50M	-$3.00	N/A	∞	N/A	-660.61%	-263.34%	-107.08%	N/A

Latest ADIL, YMTX, CVKD, and PTIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/1/2024	Q4 2023	PTIX Protagenic Therapeutics	N/A	-$0.38	-$0.38	-$0.38	N/A	N/A
3/11/2024	Q4 2023	CVKD Cadrenal Therapeutics	-$0.09	-$0.05	+$0.04	-$0.05	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	N/A
PTIX Protagenic Therapeutics	N/A	N/A	N/A	N/A	N/A
YMTX Yumanity Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	4.90	4.90
CVKD Cadrenal Therapeutics	N/A	10.27	10.27
PTIX Protagenic Therapeutics	N/A	6.41	6.41
YMTX Yumanity Therapeutics	N/A	2.21	2.21

Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
CVKD Cadrenal Therapeutics	7.92%
PTIX Protagenic Therapeutics	7.97%
YMTX Yumanity Therapeutics	25.10%

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	14.47%
CVKD Cadrenal Therapeutics	58.12%
PTIX Protagenic Therapeutics	37.00%
YMTX Yumanity Therapeutics	12.45%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	4	4.05 million	3.47 million	No Data
CVKD Cadrenal Therapeutics	4	16.01 million	6.70 million	Not Optionable
PTIX Protagenic Therapeutics	N/A	4.44 million	2.79 million	Not Optionable
YMTX Yumanity Therapeutics	40	10.86 million	9.50 million	Not Optionable

ADIL, YMTX, CVKD, and PTIX Headlines

Source	Headline
	JSPR Jasper Therapeutics, Inc. seekingalpha.com - March 20 at 7:11 PM
	Cara Therapeutics Inc CARA morningstar.com - November 3 at 7:42 AM
	Yumanity Therapeutics Inc. thestreet.com - October 6 at 6:24 PM
	Former Onyx CEO Returns to Biotech to Launch Boston Start Up thestreet.com - July 5 at 1:02 AM
	Kineta raises $6M through registered direct offering bizjournals.com - May 1 at 1:51 AM
	Colorectal Cancer Therapeutics Market Size to Surpass US$ 24.58 Billion by 2030 - Growth Plus Reports finance.yahoo.com - February 22 at 10:00 AM
	Yumanity Therapeutics's Return On Capital Employed Insights msn.com - December 26 at 1:21 PM
	Kineta finalizes reverse merger with Yumanity, secures additional funding bizjournals.com - December 20 at 6:58 PM
	Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to ... bakersfield.com - December 5 at 6:26 PM
	Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta finance.yahoo.com - December 5 at 6:26 PM
	Why Is Yumanity Therapeutics (YMTX) Stock Up Today? investorplace.com - December 5 at 3:03 PM
	Yumanity Therapeutics Inc: Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments finanznachrichten.de - November 14 at 11:42 AM
	Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments finance.yahoo.com - November 14 at 11:42 AM
	Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc. finance.yahoo.com - November 10 at 4:45 PM
	Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta finance.yahoo.com - August 29 at 10:16 AM
	Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments finance.yahoo.com - August 4 at 6:52 PM
	Glioblastoma Pipeline Analysis: Key Pharma Players Set to Develop Novel Therapies and Explore Countless Opportunities medgadget.com - July 14 at 1:51 AM
	YUMANITY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of… lawyer-monthly.com - July 5 at 10:55 PM
	Inside Kineta's plans after unveiling reverse merger deal finance.yahoo.com - June 8 at 9:39 PM
	Seattle biotech Kineta to go public in merger deal with Yumanity Therapeutics bizjournals.com - June 7 at 11:47 PM
	Short Volatility Alert: Yumanity Therapeutics, Inc. msn.com - June 7 at 6:47 PM
	Yumanity leaps as it reveals Janssen asset purchase and merger deal with Kineta thepharmaletter.com - June 6 at 5:23 PM
	Yumanity to Sell Neurosciences Candidates, Merge With Kineta >YMTX marketwatch.com - June 6 at 12:23 PM
	Yumanity stock soars 46% on all-stock merger with Kineta; lead product sale to J&J for $26M seekingalpha.com - June 6 at 12:23 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adial Pharmaceuticals

NASDAQ:ADIL

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Cadrenal Therapeutics

NASDAQ:CVKD

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Protagenic Therapeutics

NASDAQ:PTIX

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

Yumanity Therapeutics

NASDAQ:YMTX

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial